Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study

• Published in: Transplantation and cellular therapy 2023-03, Vol.29 (3), p.166.e1-166.e10
• Main Authors: Putta, Santosh, Young, Bradford A., Levine, John E., Reshef, Ran, Nakamura, Ryotaro, Strouse, Christopher, Perales, Miguel-Angel, Howard, Alan, Pine, Polly, Shi, Ju, Zhang, Peixin, Ho, Vincent T., Saber, Wael
• Format: Article
• Language: English
• Subjects: Biomarkers; Bone Marrow; Defibrotide; Hematopoietic Stem Cell Transplantation - adverse effects; Hepatic Veno-Occlusive Disease - etiology; Humans; Prognosis; Sinusoidal obstruction syndrome; Transplants; Veno-occlusive disease
• ISSN: 2666-6367; 2666-6375; 2666-6367
• DOI: 10.1016/j.jtct.2022.11.024

•Plasma biomarkers are prognostic of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) risk post-hematopoietic cell transplantation (HCT) before clinical symptoms manifest.•Plasma biomarkers are prognostic of VOD/SOS by 7 days post-HCT.•Plasma biomarkers are prognostic of disease risk independent of risk factors.•Future validation with independent datasets may guide earlier clinical intervention. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell transplantation (HCT). This study aimed to determine a blood biomarker signature early post-HCT that identifies patients at high risk for VOD/SOS. A set of 23 plasma biomarkers, selected from the VOD/SOS literature, was measured on days 0, 7, and 14 after myeloablative HCT using blood samples from patients enrolled in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1202. Eligible cases were diagnosed with VOD/SOS in BMT CTN 1202 using the Baltimore criteria. Controls (without VOD/SOS) were matched to cases for conditioning regimen and age. Significant biomarkers were identified using the Bonferroni-adjusted Wilcoxon rank-sum test (P ≤ .002). Thirty-three patients with mild or severe VOD/SOS were identified (cases) and matched to 107 controls. Two, 8, and 5 biomarkers measured from the plasma of these patients were significantly associated with the development of VOD/SOS at days 0, 7, and 14, respectively, with the strongest associations on days 7 and 14. Biomarker associations were stronger for severe VOD/SOS risk and were stronger prognostic markers for VOD/SOS cases occurring within 28 days of HCT. Hyaluronan was most strongly associated with VOD/SOS risk, with an area under the receiver operating characteristic curve (AUC) of .81 on day 7 and .79 on day 14. Multivariate models of up to 5 biomarkers generated AUCs ranging from .82 to .85. All associations with VOD/SOS risk were independent of clinical risk factors. This study confirms previously identified biomarkers of VOD/SOS risk and identified novel prognostic biomarker signatures that identify patients at risk for VOD/SOS shortly after HCT. Multivariate analysis suggests that a combination of up to 5 of these protein biomarkers may provide a prognostic tool for identifying patients at risk for VOD/SOS.